OZD-MET 01
OZD-MET 01 is a chaperone-based PROTAC-class MET protein degrader. OZD-MET 01 induces MET protein degradation in lung cancer cells in a time- and dose-dependent manner and inhibits cancer cell proliferation. OZD-MET 01 can be used in studies related to non-small cell lung cancer.
(Pink: c-Met/HGFR ligand (HY-50878); Blue: HSP90 ligand (HY-176951); Black: linker (HY-176952)).
For research use only. We do not sell to patients.
- CAS No.: 3048497-38-4
- Formula: C45H50Cl2FN7O8
- Molecular Weight:906.83
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
- Purity & Documentation
- References
-
Help & FAQs
All PROTACs Isoforms
More
Biological Activity
Description
Cellular Effect
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| NCI-H596 | IC50 |
3.07 μM
|
Inhibition of H596 cell viability assessed via CCK8 assay following 3-day treatment with OZD-MET 01, with absorbance measured at 450 nM using an ELISA reader.
Inhibition of H596 cell viability assessed via CCK8 assay following 3-day treatment with OZD-MET 01, with absorbance measured at 450 nM using an ELISA reader.
|
en?oq=WO2024144088 |
| NCI-H1437 | IC50 |
3.50 μM
|
Inhibition of H1437 cell viability assessed via CCK8 assay following 3-day treatment with OZD-MET 01, with absorbance measured at 450 nM using an ELISA reader.
Inhibition of H1437 cell viability assessed via CCK8 assay following 3-day treatment with OZD-MET 01, with absorbance measured at 450 nM using an ELISA reader.
|
en?oq=WO2024144088 |
In Vitro
OZD-MET 01 (administered consecutively for 3 days) potently inhibits the viability of H596 and H1437 cells, with IC50 values of 3.07 μM and 3.50 μM, respectively[1].
OZD-MET 01 (2.5-10 μM; 6-72 h) induces more than 50% degradation of c-MET protein in H596 and H1437 cells[1].
OZD-MET 01 (5 μM; 16 h, co-treated with 100 nM proteasome inhibitor Bortezomib (HY-10227)) mediates UPS-dependent c-MET degradation in H596 and H1437 cells, and the recovery rate of c-MET expression exceeds 50% after co-treatment with the proteasome inhibitor Bortezomib[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:H596 cells; H1437 cells
-
Concentration:2.5, 5 and 10 μM; 5 μM (standard condition)
-
Incubation Time:6, 8, 24, 48, 72 h; 72 h (standard condition)
-
Result:Induced greater than 50% degradation of c-MET protein in H596 and H1437 cells.
-
Cell Line:H596 cells; H1437 cells
-
Concentration:5 μM (co-treated with 100 nM proteasome inhibitor Bortezomib (HY-10227))
-
Incubation Time:16 h
-
Result:Mediated c-MET degradation in H596 and H1437 cells that was reversed with >50% recovery when co-treated with the proteasome inhibitor Bortezomib.
Chemical Information
-
CAS No. 3048497-38-4
-
Molecular Weight 906.83
-
Formula C45H50Cl2FN7O8
-
SMILES
C[C@@H](OC1=CC(C2=CN(N=C2)C3CCN(C(OCCOCCNC(C4=CC(CN(C(C5=CC(C(C)C)=C(O)C=C5O)=O)C)=CC=C4)=O)=O)CC3)=CN=C1N)C6=C(Cl)C(F)=CC=C6Cl
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
OZD-MET 01 Related Classifications
HY-177893 Related Classifications
Powered by Bioz